Randomized controlled trial of mibampator for behavioral and psychological symptoms of dementia: Comments on the trial and thoughts for future studies

International Psychogeriatrics

Volumn 25, Issue 5, 2013, Pages 687-689

  Ballard, Clive ^a   Francis, Paul ^a   Corbett, Anne ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMPA RECEPTOR; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CARBAMAZEPINE; CHOLINESTERASE INHIBITOR; CITALOPRAM; MEMANTINE; MIBAMPATOR; OLANZAPINE; PLACEBO; PRAZOSIN; RISPERIDONE; TRAZODONE; VALPROIC ACID;

AGGRESSION; AGITATION; ALZHEIMER DISEASE; BEHAVIOR DISORDER; DEMENTIA; DRUG EFFICACY; DRUG MECHANISM; DRUG RESEARCH; DRUG TREATMENT FAILURE; EDITORIAL; HUMAN; MENTAL DISEASE; METHODOLOGY; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC);

AGGRESSION; ALZHEIMER DISEASE; BIPHENYL COMPOUNDS; FEMALE; HUMANS; MALE; PSYCHOMOTOR AGITATION; SULFONAMIDES;

EID: 84875454931     PISSN: 10416102     EISSN: 1741203X     Source Type: Journal    
DOI: 10.1017/S1041610213000033     Document Type: Editorial

References (18)

1. Ballard, C. and Howard, R. (2006). Neuroleptic drugs in dementia: benefits and harm. Nature Reviews Neuroscience, 7, 492-500.
2. Ballard, C. et al. (2000). Delusions associated with elevated muscarinic binding in dementia with Lewy bodies. Annals of Neurology, 48, 868-876.
3. Ballard, C. et al. (2008). A randomized, blinded, placebo-controlled trial in dementia patients continuing or stopping neuroleptics (the DART-AD trial). PLoS Medicine, 5, 76.
4. Ballard, C. et al. (2009a). The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial. Lancet Neurology, 8, 151-157.
5. Ballard, C. G. et al. (2009b). Management of agitation and aggression associated with Alzheimer disease. Nature Reviews Neuroscience, 5, 245-255.
6. Bodick, N. C. et al. (1997). Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease. Archives of Neurology, 54, 465-473.
7. Corbett, A., Smith, J., Creese, B. and Ballard, C. (2012). Treatment of behavioral and psychological symptoms of Alzheimer's disease. Current Treatment Option in Neurology, 14, 113-125.
8. Fox, C. et al. (2012). Efficacy of memantine for agitation in Alzheimer's dementia: a randomised double-blind placebo controlled trial. PLoS One, 7, e35185.
9. Howard, R. J. et al. (2007). Donepezil for the treatment of agitation in Alzheimer's disease. New England Journal of Medicine, 357, 1382-1392.
10. Olin, J. T., Fox, L. S., Pawluczyk, S., Taggart, N. A. and Schneider, L. S. (2001). A pilot randomized trial of carbamazepine for behavioral symptoms in treatment-resistant outpatients with Alzheimer disease. American Journal of Geriatric Psychiatry, 9, 400-405.
11. Pollock, B. G. et al. (2007). A double-blind comparison of citalopram and risperidone for the treatment of behavioral and psychotic symptoms associated with dementia. American Journal of Geriatric Psychiatry, 15, 942-952.
12. Schneider, L. S., Dagerman, K. and Insel, P. S. (2006a). Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. American Journal of Geriatric Psychiatry, 14, 191-210.
13. Schneider, L. S. et al. (2006b). Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. New England Journal of Medicine, 355, 1525-1538.
14. Sharp, S. I., Ballard, C. G., Chen, C. P. and Francis, P. T. (2007). Aggressive behavior and neuroleptic medication are associated with increased number of alpha1-adrenoceptors in patients with Alzheimer disease. American Journal of Geriatric Psychiatry, 15, 435-437.
15. Tariot, P. N. et al. (1998). Efficacy and tolerability of carbamazepine for agitation and aggression in dementia. American Journal of Geriatric Psychiatry, 155, 54-61.
16. Teaktong, T., Piggott, M. A., Mckeith, I. G., Perry, R. H., Ballard, C. G. and Perry, E. K. (2005). Muscarinic M2 and M4 receptors in anterior cingulate cortex: relation to neuropsychiatric symptoms in dementia with Lewy bodies. Behavioural Brain Research, 161, 299-305.
17. Trzepacz, P. T. et al. (2013). Mibampator (LY451395) randomized clinical trial for agitation/aggression in Alzheimer's disease. International Psychogeriatrics, 25, 707-719.
18. Wang, L. Y. et al. (2009). Prazosin for the treatment of behavioral symptoms in patients with Alzheimer disease with agitation and aggression. American Journal of Geriatric Psychiatry, 17, 744-751.